Methodological Issues Surrounding the Use of Baseline Health-Related Quality of Life Data to Inform Trial-Based Economic Evaluations of Interventions Within Emergency and Critical Care Settings: A Systematic Literature Review
- 263 Downloads
Trial-based cost-utility analyses require health-related quality of life data that generate utility values in order to express health outcomes in terms of quality-adjusted life years (QALYs). Assessments of baseline health-related quality of life are problematic where trial participants are incapacitated or critically ill at the time of randomisation. This review aims to identify and critique methods for handling non-availability of baseline health-related quality of life data in trial-based cost-utility analyses within emergency and critical illness settings.
A systematic literature review was conducted, following PRISMA guidelines, to identify trial-based cost-utility analyses of interventions within emergency and critical care settings. Databases searched included the National Institute for Health Research (NIHR) Journals Library (1991–July 2016), Cochrane Library (all years); National Health Service (NHS) Economic Evaluation Database (all years) and Ovid MEDLINE/Embase (without time restriction). Strategies employed to handle non-availability of baseline health-related quality of life data in final QALY estimations were identified and critiqued.
A total of 4224 published reports were screened, 19 of which met the study inclusion criteria (mean trial size 1670): 14 (74 %) from the UK, four (21%) from other European countries and one (5%) from India. Twelve studies (63%) were based in emergency departments and seven (37%) in intensive care units. Only one study was able to elicit patient-reported health-related quality of life at baseline. To overcome the lack of baseline data when estimating QALYs, eight studies (42%) assigned a fixed utility weight corresponding to either death, an unconscious health state or a country-specific norm to patients at baseline, four (21%) ignored baseline utilities, three (16%) applied values from another study, one (5%) generated utility values via retrospective recall and one (5%) elicited utilities from experts. A preliminary exploration of these methods shows that incremental QALY estimation is unlikely to be biased if balanced trial allocation is achieved and subsequent collection of health-related quality of life data occurs at the earliest possible opportunity following commencement of treatment, followed by an adequate number of follow-up assessments.
Trial-based cost-utility analyses within emergency and critical illness settings have applied different methods for QALY estimation, employing disparate assumptions about the health-related quality of life of patients at baseline. Where baseline measurement is not practical, measurement at the earliest opportunity following commencement of treatment should minimise bias in QALY estimation.
The concept of this manuscript was jointly conceived by Melina Dritsaki, Felix Achana, and Stavros Petrou. Melina Dritsaki and Felix Achana gathered and reviewed the literature and data and drafted the initial manuscript. James Mason drafted the initial work presented in Sect. 4. All authors participated in the interpretation of data and preparation of the final manuscript.
Compliance with Ethical Standards
Melina Dritsaki, Felix Achana, James Mason, and Stavros Petrou have no conflicts of interest to disclose. There was no research funding support for this study.
Data availability statement
The authors declare that the data supporting the findings of this study are available within the article and its supplementary information files.
- 1.Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic evaluation in clinical trials. Oxford: Oxford University Press; 2007.Google Scholar
- 3.CDR Directorate at Canadian Coordinating Office for Health Technology Assessment. Canada common drug review submission guidelines for manufacturers. CCOHTA, 2013.Google Scholar
- 4.Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee. Canberra: PBAC; 2002.Google Scholar
- 9.Devlin N, Shah K, Feng Y, Mulhern B, Van Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England. Research Paper 16/01, Office of Health Economics; 2016.Google Scholar
- 13.Gates S, et al. Beta-Agonist Lung injury TrIal-2 (BALTI-2): a multicentre, randomised, double-blind, placebo-controlled trial and economic evaluation of intravenous infusion of salbutamol versus placebo in patients with acute respiratory distress syndrome. Health Technol Assess. 2013;17(38): v–vi, 1–87.Google Scholar
- 16.Goodacre S, et al. The RATPAC (Randomised Assessment of Treatment using Panel Assay of Cardiac markers) trial: a randomised controlled trial of point-of-care cardiac markers in the emergency department. Health Technol Assess. 2011;15(23):iii–xi, 1–102.Google Scholar
- 19.Powell CV, et al. MAGNEsium Trial In Children (MAGNETIC): a randomised, placebo-controlled trial and economic evaluation of nebulised magnesium sulphate in acute severe asthma in children. Health Technol Assess. 2013;17(45):v–vi, 1–216.Google Scholar
- 22.Moher D, LiberatiA, Tetzlaff J, Altman DG, The PRISMA Group. The PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine (OPEN ACCESS). 2009.Google Scholar
- 26.Lall R, et al. A randomised controlled trial and cost-effectiveness analysis of high-frequency oscillatory ventilation against conventional artificial ventilation for adults with acute respiratory distress syndrome. The OSCAR (OSCillation in ARDS) study. Health Technol Assess. 2015;19(23):1–177, vii.Google Scholar
- 27.Rosenthal VD, Udwadia FE, Kumar S, Poojary A, Sankar R, Orellano PW, Durgad S, Thulasiraman M, Bahirune S, Kumbhar S, Patil P. Clinical impact and cost-effectiveness of split-septum and single-use prefilled flushing device vs 3-way stopcock on central line-associated bloodstream infection rates in India: a randomized clinical trial conducted by the International Nosocomial Infection Control Consortium (INICC). Am J Infect Control. 2015;43:1040–1045.Google Scholar
- 29.Harvey S, et al. An evaluation of the clinical and cost-effectiveness of pulmonary artery catheters in patient management in intensive care: a systematic review and a randomised controlled trial. Health Technol Assess. 2006;10(29):iii–iv, ix–xi, 1–133.Google Scholar
- 30.National Institute for Health and Clinical Excellence. NICE guide to the methods of technology appraisal. NICE, 2013.Google Scholar
- 32.Sierink JC, Treskes K, Edwards MJR, Beuker BJA, den Hartog D, Hohmann J, Dijkgraaf MGW, Luitse JSK, Beenen LFM, Hollmann MW, Goslings JC, For the REACT-2 study group*. Immediate total-body CT scanning versus conventional imaging and selective CT scanning in patients with severe trauma (REACT-2): a randomised controlled trial. Lancet. 2016;388:673–83.Google Scholar
- 34.Sintonen H. Comparing properties of the 15D and the EQ-5D in measuring health-related quality of life. Arch Hellen Med. 2001;18(2):156–160.Google Scholar
- 42.Lamb SE, et al. Managing Injuries of the Neck Trial (MINT): a randomised controlled trial of treatments for whiplash injuries. Health Technol Assess. 2012;16(49):iii–iv, 1–141.Google Scholar